



A Strategy for the Extraction and Analysis of Perfluoroalkyl Substances (PFAS) in Human Serum Using Weak Anion Exchange Chemistry

Kari Organtini
Senior Scientist
NEMC 2020

Perfluoroalkylated Substances (PFAS)


- PFAS = PFC = AFFF
- First **created** in the **1930s**
- **Widespread applications**
 - Non stick **coatings**, **surfactants**, food **packaging**, firefighting **foams**
 - **Polymerization aid** for polytetrafluoroethylene (PTFE) and other fluoropolymers – how PFOS and PFOA became famous
- **Stable** and **persistent** in the environment (POP)
 - Bio-accumulative
- **Identified** in environmental samples **worldwide**
 - Found in arctic **polar bears**





NHANES Studies on PFAS in Human Serum

- 1999-2016
- Age, gender, and race
- 12 PFAS detected in human serum:
 - PFBS
 - PFDA
 - PFDoDA
 - PFHpA
 - PFHxS
 - PFNA
 - PFUnDA
 - PFOA (branched and linear)
 - PFOS (branched and linear)
 - PFOSA (aka FOSA)
 - NETFOSAA
 - NMeFOSAA



Finding a measurable amount of PFCs in serum does not imply that the levels of PFCs cause an adverse health effect. Biomonitoring studies of serum PFCs can provide physicians and public health officials with reference values so that they can determine whether or not people have been exposed to higher levels of PFCs than are found in the general population. Biomonitoring data can also help scientists plan and conduct research on exposure and health effects.


https://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Volume1_Jan2019-508.pdf

https://www.cdc.gov/biomonitoring/PFAS_BiomonitoringSummary.html


Transitioning from Water to Serum



Solid Phase Extraction Set Up - Cartridge



Solid Phase Extraction Set Up – 96 well plate



Wide variety of chemical properties

Waters


THE SCIENCE OF WHAT'S POSSIBLE.™



Perfluoro Carboxylic Acid
(PFOA)




Perfluoro Sulfonic Acid
(PFOS)




Sulfonamidoacetic
acid
(N-EtFOSAA)



Perfluoro Telomer Acid
(FHEA or 6:2 FTA)




Perfluoro Telomer Sulfonate
(6:2 FTS)





Emerging PFAS
(GenX)

Cyclic
(PFechS)



30 PFAS targeted in method

<p style="text-align: center;"><u>Carboxylates</u></p>  <p style="text-align: center;">C4 – C14</p>	<p style="text-align: center;"><u>Sulfonates</u></p>  <p style="text-align: center;">C4 – C10</p>						
<p style="text-align: center;"><u>Emerging</u></p> <table style="width: 100%; text-align: center;"> <tr> <td>GenX</td> <td>ADONA</td> </tr> <tr> <td>11CI-PF3OUdS</td> <td>9CI-PF3ONS</td> </tr> <tr> <td>FBSA</td> <td>FHxSA</td> </tr> </table>	GenX	ADONA	11CI-PF3OUdS	9CI-PF3ONS	FBSA	FHxSA	<p style="text-align: center;"><u>Precursors</u></p> <p style="text-align: center;">4:2/6:2/8:2 FTS</p> <p style="text-align: center;">FOSA</p> <p style="text-align: center;">NMeFOSAA/NEtFOSAA</p>
GenX	ADONA						
11CI-PF3OUdS	9CI-PF3ONS						
FBSA	FHxSA						

Instrument Methods

Source Parameters

- Instrument: Xevo TQ-S micro
- Ion Mode: ESI-
- Capillary Voltage: 0.5 kV
- Desolvation Temperature: 300° C
- Desolvation Flow: 900 L/hr
- Cone Flow: 100 L/hr

MS Method


- Developed using QuanOptimize
 - MRMs, CV, CE
- Divert flow to waste from 0 – 3 and 16 – 22 mins

LC Method

- Instrument: Acquity I Class PLUS **modified with PFAS Kit**
- Column: HSS T3 2.1mm x 100 mm, 1.8 µm
- Mobile Phase A: 95:5 H2O:MeOH + 2 mM ammonium acetate
- Mobile Phase B: MeOH + 2 mM ammonium acetate
- Injection Volume: 5 µL
- Gradient:

Time (min)	Flow (mL/min)	%A	%B
0	0.3	100	0
1	0.3	80	20
6	0.3	55	45
13	0.3	20	80
14	0.4	5	95
17	0.4	5	95
18	0.3	100	0
22	0.3	100	0

Introduction to Weak Anion eXchange (WAX)



SPE Sample Preparation

Pretreat Samples (50 μ L)

pH adjust to < 3 – **activates ion exchange sites in WAX sorbent when loaded**

Condition Plate

Load Sample

Wash Plate

Elute

Eluent with pH > 8 – **“turns off” ion exchange sites in WAX sorbent to release PFAS**


Waters
THE SCIENCE OF WHAT'S POSSIBLE



Oasis WAX 96 well
 μ Elution plate

2 mg per well

SPE Sample Preparation



Oasis WAX 96 well
µElution plate
2 mg per well

SPE Sample Preparation

Pretreat Samples (50 μ L) ★

pH adjust to < 3 – **activates ion exchange sites in WAX sorbent when loaded**

Condition Plate

Load Sample

Wash Plate ★

Elute

Eluent with pH > 8 – **“turns off” ion exchange sites in WAX sorbent to release PFAS**

Waters
THE SCIENCE OF WHAT'S POSSIBLE



Oasis WAX 96 well
 μ Elution plate

2 mg per well

SPE Sample Preparation

Pretreat Samples (50 µL) ★
pH adjust to < 3 – **activates ion exchange sites in WAX sorbent when loaded**

Condition Plate

Load Sample

Wash Plate ★


Elute

Eluent with pH > 8 – **“turns off” ion exchange sites in WAX sorbent to release PFAS**

- 1:3 serum:50% Formic Acid
- 1:1 serum:ACN
- 1:3 serum:ACN
- 1:1 serum:MeOH

Dilute sample 5x in 1% Aqueous Formic Acid

SPE Sample Preparation



- 2% Formic Acid
+
- 100% ACN
 - 1:1 ACN:H2O
 - 1:3 ACN:H2O
 - No 2nd Wash

SPE Sample Preparation – Final Method

Pretreat Samples (50 μ L) – spike isotope dilution standards, PPT with 3x ACN, dilute with 5x 1% Formic Acid

Condition Plate

200 μ L 2% ammonia/methanol
200 μ L methanol
200 μ L 1% Formic Acid

Load Sample

Wash Plate

200 μ L 1% Formic Acid
200 μ L 1:3 ACN:Water

Elute

50 μ L methanol
50 μ L 2% (v/v) ammonia/methanol \rightarrow 2x
Dilute with 50 μ L 2% ammonium acetate containing Injection Standards

Waters
THE SCIENCE OF WHAT'S POSSIBLE




Oasis WAX 96 well
 μ Elution plate

2 mg per well






FBS Curves

R² for PFAS using FBS extracted curves



Cal points of 0.05 – 20 ng/L Waters


THE SCIENCE OF WHAT'S POSSIBLE.™



Recovery in Fetal Bovine Serum


Pre and Post Spike area over calibration range:
0.05, 0.1, 0.5, 1.0, 2.5, 5, 10 and 20 ng/L

Average Recovery in FBS



Recovery in Human Serum

Pre and Post Spike area at 0.1, 1.0, and 10 ng/L




Recovery in Human Serum


6 Lots of Pooled Human Serum

Pre and Post Spike area at 0.1, 1.0, and 10 ng/L


Average Recovery - 6 Lots Human Serum



Internal Standards



Recoveries Corrected with Internal Standards




Certificate of Analysis

Standard Reference Material® 1957

Organic Contaminants in Non-Fortified Human Serum
(Freeze-Dried)


“Extra” Compounds Detected

Compound	ng/ml
NMeFOSAA	1.01
NEtFOSAA	0.19
PFHpS	0.30
PFBA	< MQL
PFPeA	< MQL




Human Pooled Samples

Lot 1




Total PFAS = 18.96 ng/L

Lot 2



Total PFAS = 14.44 ng/L


Lot 3




Total PFAS = 8.86 ng/L

Linear and Branched Isomers

PFOS isomers in Human Serum



PFOS isomers in Standard



Sometimes SPE can't remove it all...

Anal Bioanal Chem (2015) 407:3751–3761
DOI 10.1007/s00216-015-8601-x

RESEARCH PAPER

An automated high-throughput SPE micro-elution method for perfluoroalkyl substances in human serum

Sandra Huber · Jan Brox

Three MRM transitions were implemented for PFHxS and PFOS in order to monitor separation of the potentially interfering endogenous steroid sulphates [34, 39] and bile acids [39]. In addition, a chromatographic separation of the PFAS compounds and the mentioned interferences of 0.3 min at least were set as criteria (Figs. 1, 2 and Electronic Supplementary

Waters
THE SCIENCE OF WHAT'S POSSIBLE.™

RCM

RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Rapid Commun. Mass Spectrom. 2009; 23: 1405–1410

Published online in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/rcm.4012

Endogenous high-performance liquid chromatography/tandem mass spectrometry interferences and the case of perfluorohexane sulfonate (PFHxS) in human serum; are we overestimating exposure?


Emily Chan¹, Mandeep Sandhu², Jonathan P. Benskin², Milan Ralitsch³, Nicole Thibault³, Detlef Birkholz³ and Jonathan W. Martin^{1,2*}

MS).^{10,11,13–27} The challenges of PFA analytical methods have been reviewed,²⁸ but, for PFOS in particular, the very first report of it in human serum¹¹ noted the presence of a co-eluting MS/MS interference in the most sensitive MS/MS transition (i.e. m/z 499/80) – later identified as taurodeoxycholate isomers²⁹ – which could cause significant over-reporting of concentrations. For PFHxS ($C_6F_{13}SO_3^-$; m/z 399), almost all existing data has been generated using its most sensitive MS/MS transitions: m/z 399/80 ($[SO_3]^-$) or m/z 399/99 ($[SO_3F]^-$).^{11,19–21,23–25,27,30} However, it is now unclear whether the existing PFHxS data may be systematically biased as a result of co-eluting endogenous interferences in pooled maternal serum which share both these MS/MS transitions:²⁹ the major source being 5-pregnane-3,20-diol-2-sulfate, commonly known as pregnandiol sulfate, and the minor source being ³⁴S-3-hydroxy-5pregnan-20-one sulfate, commonly known as isopregnanalone sulfate.

Matrix Interference


Pregnane-3,20-diol 3-sulfate

Molecular Weight: 400.6 g/mol




3alpha-Hydroxy-5alpha-pregnan-20-one sulfate

Molecular Weight: 398.6 g/mol



Perfluorohexanesulfonic acid




Molecular Weight: 400.12 g/mol



PFHxS Matrix Interference – BEH C18

Waters

Acquity BEH C18




PFHxS Matrix Interference – HSS T3

Waters

THE SCIENCE OF WHAT'S POSSIBLE.™

Acquity HSS T3



Acknowledgements

- Mary Lame
- Lisa Calton
- Ken Rosnack
- Keil Brinster



Complete PFAS Solutions

Waters
THE SCIENCE OF WHAT'S POSSIBLE.™

2020 Proficiency Testing Scheme Schedule

 **ERA**
www.eraqc.com

